Literature DB >> 11385014

Increased plasma neurotensin concentrations in patients with Parkinson's disease.

R M Schimpff1, C Avard, G Fénelon, A M Lhiaubet, L Tennezé, M Vidailhet, W Rostène.   

Abstract

Plasma neurotensin (NT) was measured by radioimmunoassay in propanol extracted and unextracted plasma from 16 parkinsonian patients (four before treatment) and 16 age and sex matched controls. Mean plasma NT concentrations were consistently higher in parkinsonian patients than in controls and higher in the four untreated patients than in levodopa treated patients suggesting that plasma NT measurement may represent an easy detectable additional index in diagnosing parkinsonism and provides a novel approach to research in this field.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11385014      PMCID: PMC1737416          DOI: 10.1136/jnnp.70.6.784

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  18 in total

1.  Modulation of the interaction between neurotensin receptor NTS1 and Gq protein by lipid.

Authors:  Sayaka Inagaki; Rodolfo Ghirlando; Jim F White; Jelena Gvozdenovic-Jeremic; John K Northup; Reinhard Grisshammer
Journal:  J Mol Biol       Date:  2012-01-27       Impact factor: 5.469

2.  Cross-receptor interactions between dopamine D2L and neurotensin NTS1 receptors modulate binding affinities of dopaminergics.

Authors:  Susanne Koschatzky; Nuska Tschammer; Peter Gmeiner
Journal:  ACS Chem Neurosci       Date:  2011-04-11       Impact factor: 4.418

Review 3.  The role of neurotensin in central nervous system pathophysiology: what is the evidence?

Authors:  Fannie St-Gelais; Claudia Jomphe; Louis-Eric Trudeau
Journal:  J Psychiatry Neurosci       Date:  2006-07       Impact factor: 6.186

4.  Structure of signaling-competent neurotensin receptor 1 obtained by directed evolution in Escherichia coli.

Authors:  Pascal Egloff; Matthias Hillenbrand; Christoph Klenk; Alexander Batyuk; Philipp Heine; Stefanie Balada; Karola M Schlinkmann; Daniel J Scott; Marco Schütz; Andreas Plückthun
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-22       Impact factor: 11.205

Review 5.  Neuroprotective Effects of Brain-Gut Peptides: A Potential Therapy for Parkinson's Disease.

Authors:  Dong Dong; Junxia Xie; Jun Wang
Journal:  Neurosci Bull       Date:  2019-07-08       Impact factor: 5.203

6.  Discovery of β-Arrestin Biased, Orally Bioavailable, and CNS Penetrant Neurotensin Receptor 1 (NTR1) Allosteric Modulators.

Authors:  Anthony B Pinkerton; Satyamaheshwar Peddibhotla; Fusayo Yamamoto; Lauren M Slosky; Yushi Bai; Patrick Maloney; Paul Hershberger; Michael P Hedrick; Bekhi Falter; Robert J Ardecky; Layton H Smith; Thomas D Y Chung; Michael R Jackson; Marc G Caron; Lawrence S Barak
Journal:  J Med Chem       Date:  2019-08-20       Impact factor: 7.446

7.  MiRNA mimic screen for improved expression of functional neurotensin receptor from HEK293 cells.

Authors:  Su Xiao; Yu-Chi Chen; Michael J Betenbaugh; Scott E Martin; Joseph Shiloach
Journal:  Biotechnol Bioeng       Date:  2015-06-16       Impact factor: 4.530

Review 8.  Biophysical characterization of membrane proteins in nanodiscs.

Authors:  Sayaka Inagaki; Rodolfo Ghirlando; Reinhard Grisshammer
Journal:  Methods       Date:  2012-12-03       Impact factor: 3.608

Review 9.  Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration.

Authors:  P S Vosler; C S Brennan; J Chen
Journal:  Mol Neurobiol       Date:  2008-08-07       Impact factor: 5.590

10.  Preventive Effect of Two New Neurotensin Analogues on Parkinson's Disease Rat Model.

Authors:  Maria Lazarova; Andrey Popatanasov; Radoslav Klissurov; Svetlana Stoeva; Tamara Pajpanova; Reni Kalfin; Lyubka Tancheva
Journal:  J Mol Neurosci       Date:  2018-10-30       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.